# Niraparib In Recurrent IDH 1/2 Gliomas

> **NCT05406700** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 16 (estimated)

## Conditions studied

- Low-grade Glioma
- IDH2 Gene Mutation
- Recurrent Glioma
- IDH1 Mutation
- Glioma, Malignant

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Resection/Treatment with Niraparib

## Key facts

- **NCT ID:** NCT05406700
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-18
- **Primary completion:** 2026-07
- **Final completion:** 2026-10
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05406700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05406700, "Niraparib In Recurrent IDH 1/2 Gliomas". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT05406700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*